Develops drugs for growth hormone deficiency and chronic kidney disease.
Jun 2026Revenue $588M/yrExpenses $636M/yr
No trendCash runway ≈ 2.4 years from Jun 2026
Figures by year
When will Opko Health be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $588M and expenses $636M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $607M | $724M | −$117M |
| Dec 2024 | $713M | $865M | −$152M |
| Dec 2023 | $863M | $1.02B | −$157M |
| Dec 2022 | $1.00B | $1.23B | −$226M |
| Dec 2021 | $1.77B | $1.76B | $18.8M |
| Dec 2020 | $1.44B | $1.38B | $57.7M |
| Dec 2019 | $902M | $1.18B | −$274M |
| Dec 2018 | $990M | $1.16B | −$171M |
| Dec 2017 | $966M | $1.24B | −$276M |
| Dec 2016 | $1.12B | $1.21B | −$96.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.